BioLife Solutions, Inc. (BLFS) closed the last trading session at $22.03, gaining 3.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.22 indicates a 41.7% upside potential.The average comprises nine short-term price targets ranging from a low of $30 to a high of $34, with a standard deviation of $1.48. While the lowest estimate indicates an increase of 36.2% from the current p ...

Core Insights - BioLife Solutions, Inc. is a prominent developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company is actively participating in several upcoming investor conferences, indicating a focus on investor relations and market engagement [3] Company Overview - BioLife Solutions specializes in solutions that preserve the health and functionality of biological materials throughout their lifecycle, including collection, development, storage, and distribution [1] Upcoming Investor Conferences - The company will participate in the following conferences: - 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025, in Minneapolis, MN [3] - Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, virtually [3] - Jefferies Global Life Sciences Conference from June 3 to June 5, 2025, in New York, NY [3] - Wolfe Research Small & Mid-Cap Conference on June 5, 2025, in New York, NY [3] - Northland Growth Conference 2025 on June 25, 2025, virtually [3]

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 8.2% recently, with a mean price target of $31.22 suggesting a potential upside of 30.7% from the current price of $23.89 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1.48, indicating variability among analysts [2] - The lowest price target is $30, representing a 25.6% increase, while the highest target is $34, indicating a potential surge of 42.3% [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about BLFS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 19.2% over the past month, with no negative revisions [12] - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.01, delivering a surprise of 83.33%.Over the last four quarters, t ...

BioLife Solutions (BLFS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Troy Wichterman - CFORod de Greef - Chairman & CEOPaul Knight - Managing DirectorChad Wiatrowski - VP - Equity ResearchCarl Byrnes - Managing Director Conference Call Participants Matthew Stanton - AnalystThomas Flaten - Senior Research AnalystMatthew Hewitt - Senior Research AnalystYi Chen - Managing Director & Senior Analyst Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to t ...

BioLife Solutions (BLFS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions First Quarter twenty twenty five Shareholder and Analyst Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. I will now turn the call over to Troy Wickerman, Chief Financial Officer of BioLife Solutions. Please go ahead. Speake ...

BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally.About BioLife SolutionsBioLife is a leading developer and suppli ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 ____________________________________________________ BioLife Solutions, Inc. (Exact name of registrant as specified in i ...

3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports First Quarter 2025 Financial Results Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (May 8, 2025) – BioLife Solutions, Inc. (Nasdaq: BLFS ...

Cell Processing revenue of $21.6 million, up 33% over Q1 2024GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66%GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenueConference call begins at 4:30 p.m. Eastern time todayBOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces ...